Priya Vijayvargiya1, Michael Camilleri2, Victor Chedid1, Paula Carlson1, Irene Busciglio1, Duane Burton1, Leslie J Donato3. 1. Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota. 2. Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota. Electronic address: camilleri.michael@mayo.edu. 3. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Abstract
BACKGROUND & AIMS: Patients with bile acid diarrhea (BAD) are identified based on increased levels of BAs in fecal samples collected over a 48-hr period while on a 100-gram fat diet (48-hr BA), retention of 75Se-labeled homocholic acid taurine, or serum levels of C4 or FGF19. BAD increases fecal weight and colonic transit. We investigated whether results of tests for BAD associate with increased fecal weight and more rapid colonic transit over a 24- or 48-hr period in patients with irritable bowel syndrome with diarrhea (IBS-D). We also estimated the prevalence of increased 48-hr fecal BAs in patients with chronic diarrhea. METHODS: We performed a retrospective study of 64 patients with IBS-D, 30 patients with IBS-constipation, 30 healthy volunteers (controls). We collected data on fecal weights (measured over a 48-hr period), colonic transit over a 24-hr period (measured by scintigraphy), and percentages of different BAs in stool samples. Colonic transit was measured as the geometric center (weighted average) of colonic counts on a scale of 1 (100% in ascending colon) to 5 (100% in stool). We performed area under the curve (AUC) analyses to assess the association between result of serum and stool tests and high fecal weight (>400g/48 hrs) or rapid colonic transit (>3.34, corresponding to isotope geometric center in sigmoid colon). We estimated the prevalence of increased 48-hr fecal BAs among 938 patients with chronic diarrhea. RESULTS: Total fecal 48-hr BA alone, or in combination with percentage of primary fecal BAs, identified patients with increased fecal weight with an AUROC of 0.86. Percentage of primary fecal BA alone identified patients with increased fecal weight with an AUROC of 0.73. Total fecal 48-hr BA alone identified patients with increased colonic transit with an AUROC of 0.65 and percentage of primary fecal BA alone identified patients with increased colonic transit with an AUROC of 0.69; combined data on these features identified patients with increased colonic transit with an AUROC of 0.70. Serum level of C4 identified patients with increased colonic transit with an AUROC of 0.60. Primary BAs >10% identified patients with increased fecal weight (sensitivity 49% and specificity 91%) and rapid colonic transit (sensitivity 48% and specificity 87%). Among the patients with chronic diarrhea, 45.6% had fecal primary BAs >10% and 27% had increased total fecal BAs (>2337 μmol/48 hrs). CONCLUSIONS: In a retrospective analysis of patients with IBS-D, we found percentage of primary BAs in fecal samples to provide an alternative to total fecal BAs in identification of patients with BAD or chronic diarrhea.
BACKGROUND & AIMS:Patients with bile acid diarrhea (BAD) are identified based on increased levels of BAs in fecal samples collected over a 48-hr period while on a 100-gram fat diet (48-hr BA), retention of 75Se-labeled homocholic acid taurine, or serum levels of C4 or FGF19. BAD increases fecal weight and colonic transit. We investigated whether results of tests for BAD associate with increased fecal weight and more rapid colonic transit over a 24- or 48-hr period in patients with irritable bowel syndrome with diarrhea (IBS-D). We also estimated the prevalence of increased 48-hr fecal BAs in patients with chronic diarrhea. METHODS: We performed a retrospective study of 64 patients with IBS-D, 30 patients with IBS-constipation, 30 healthy volunteers (controls). We collected data on fecal weights (measured over a 48-hr period), colonic transit over a 24-hr period (measured by scintigraphy), and percentages of different BAs in stool samples. Colonic transit was measured as the geometric center (weighted average) of colonic counts on a scale of 1 (100% in ascending colon) to 5 (100% in stool). We performed area under the curve (AUC) analyses to assess the association between result of serum and stool tests and high fecal weight (>400g/48 hrs) or rapid colonic transit (>3.34, corresponding to isotope geometric center in sigmoid colon). We estimated the prevalence of increased 48-hr fecal BAs among 938 patients with chronic diarrhea. RESULTS: Total fecal 48-hr BA alone, or in combination with percentage of primary fecal BAs, identified patients with increased fecal weight with an AUROC of 0.86. Percentage of primary fecal BA alone identified patients with increased fecal weight with an AUROC of 0.73. Total fecal 48-hr BA alone identified patients with increased colonic transit with an AUROC of 0.65 and percentage of primary fecal BA alone identified patients with increased colonic transit with an AUROC of 0.69; combined data on these features identified patients with increased colonic transit with an AUROC of 0.70. Serum level of C4 identified patients with increased colonic transit with an AUROC of 0.60. Primary BAs >10% identified patients with increased fecal weight (sensitivity 49% and specificity 91%) and rapid colonic transit (sensitivity 48% and specificity 87%). Among the patients with chronic diarrhea, 45.6% had fecal primary BAs >10% and 27% had increased total fecal BAs (>2337 μmol/48 hrs). CONCLUSIONS: In a retrospective analysis of patients with IBS-D, we found percentage of primary BAs in fecal samples to provide an alternative to total fecal BAs in identification of patients with BAD or chronic diarrhea.
Authors: P A Bampton; P G Dinning; M L Kennedy; D Z Lubowski; I J Cook Journal: Am J Physiol Gastrointest Liver Physiol Date: 2002-03 Impact factor: 4.052
Authors: Banny S Wong; Michael Camilleri; Paula Carlson; Sanna McKinzie; Irene Busciglio; Olga Bondar; Roy B Dyer; Jesse Lamsam; Alan R Zinsmeister Journal: Clin Gastroenterol Hepatol Date: 2012-05-18 Impact factor: 11.382
Authors: Alexa R Weingarden; Chi Chen; Ningning Zhang; Carolyn T Graiziger; Peter I Dosa; Clifford J Steer; Megan K Shaughnessy; James R Johnson; Michael J Sadowsky; Alexander Khoruts Journal: J Clin Gastroenterol Date: 2016-09 Impact factor: 3.062
Authors: P Vijayvargiya; M Camilleri; P Carlson; A Lueke; J O'Neill; D Burton; I Busciglio; L Donato Journal: Aliment Pharmacol Ther Date: 2017-07-10 Impact factor: 8.171
Authors: M Camilleri; A Acosta; I Busciglio; A Boldingh; R B Dyer; A R Zinsmeister; A Lueke; A Gray; L J Donato Journal: Aliment Pharmacol Ther Date: 2015-01-16 Impact factor: 8.171
Authors: H Duboc; D Rainteau; S Rajca; L Humbert; D Farabos; M Maubert; V Grondin; P Jouet; D Bouhassira; P Seksik; H Sokol; B Coffin; J M Sabaté Journal: Neurogastroenterol Motil Date: 2012-02-22 Impact factor: 3.598
Authors: Farzad Alemi; Daniel P Poole; Jonathan Chiu; Kristina Schoonjans; Fiore Cattaruzza; John R Grider; Nigel W Bunnett; Carlos U Corvera Journal: Gastroenterology Date: 2012-10-03 Impact factor: 22.682
Authors: Andrea Shin; Michael Camilleri; Priya Vijayvargiya; Irene Busciglio; Duane Burton; Michael Ryks; Deborah Rhoten; Alan Lueke; Amy Saenger; Adam Girtman; Alan R Zinsmeister Journal: Clin Gastroenterol Hepatol Date: 2013-04-30 Impact factor: 11.382
Authors: Priya Vijayvargiya; Daniel Gonzalez Izundegui; Gerardo Calderon; Sarah Tawfic; Sarah Batbold; Michael Camilleri Journal: Am J Gastroenterol Date: 2020-07 Impact factor: 10.864
Authors: Ivan Lyutakov; Francesco Ursini; Plamen Penchev; Giacomo Caio; Antonio Carroccio; Umberto Volta; Roberto De Giorgio Journal: BMC Gastroenterol Date: 2019-11-14 Impact factor: 3.067
Authors: Richard N Appleby; Iman Moghul; Shahid Khan; Michael Yee; Pinelope Manousou; Tracy Dew Neal; Julian R F Walters Journal: PLoS One Date: 2019-01-25 Impact factor: 3.240
Authors: Alison C Manchester; Craig B Webb; Amanda B Blake; Fatima Sarwar; Jonathan A Lidbury; Jörg M Steiner; Jan S Suchodolski Journal: J Vet Intern Med Date: 2019-10-31 Impact factor: 3.333